Literature DB >> 1373295

Monoclonal antibodies in the detection of bone marrow metastases in small cell lung cancer.

B G Skov1, F R Hirsch, L Bobrow.   

Abstract

Using conventional examination (CE) of H&E stained slides from bone marrow aspirates, metastases can be detected in approximately 25% of patients with small cell lung cancer. We investigated a panel of monoclonal antibodies using immunohistochemistry in the diagnosis of bone marrow infiltration from SCLC and compared the results with CE. Seven monoclonal antibodies raised against epithelial antigens (CAM 5.2, MOV 15, NCCST 433, PE 35, LCA1/L38, HMFG 1 AND HMFG 2) were applied on bone marrow sections from three groups of patients (pts): (1) 19 pts in whom SCLC-metastases were detected by CE, (2) 44 pts with SCLC in whom metastases could not be detected by CE, and (3) 20 pts with non-malignant bone marrow diseases. All the antibodies except LCA1/L38 were positive in 60-90% of the slides with infiltrating tumour cells in group 1. No positive tumour cells were detected in group 2. A few plasma cells and megakaryocytes were slightly positive for MOV 15 and NCCST 433, but no other positive cells were detected in group 3. In conclusion, the monoclonal antibodies used in this study may be useful for diagnostic purposes when a suspicious looking infiltration is detected by CE. However, these antibodies could not detect metastatic tumour cells in the bone marrow sections from patients in whom CE did not reveal any tumour cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1373295      PMCID: PMC1977544          DOI: 10.1038/bjc.1992.120

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  7 in total

1.  Monoclonal antibodies detect occult breast carcinoma metastases in the bone marrow of patients with early stage disease.

Authors:  R J Cote; P P Rosen; T B Hakes; M Sedira; M Bazinet; D W Kinne; L J Old; M P Osborne
Journal:  Am J Surg Pathol       Date:  1988-05       Impact factor: 6.394

2.  Immunocytological detection of residual marrow disease at clinical remission predicts metastatic relapse in small cell lung cancer.

Authors:  R C Leonard; L W Duncan; F G Hay
Journal:  Cancer Res       Date:  1990-10-15       Impact factor: 12.701

3.  Bone marrow involvement in small cell anaplastic carcinoma of the lung: prognostic and therapeutic aspects.

Authors:  F R Hirsch; H H Hansen
Journal:  Cancer       Date:  1980-07-01       Impact factor: 6.860

4.  Detection of bone marrow metastasis in small-cell lung cancer by monoclonal antibody.

Authors:  R A Stahel; M Mabry; A T Skarin; J Speak; S D Bernal
Journal:  J Clin Oncol       Date:  1985-04       Impact factor: 44.544

5.  Bone-marrow examination in the staging of small-cell anaplastic carcinoma of the lung with special reference to subtyping. An evaluation of 203 consecutive patients.

Authors:  F Hirsch; H H Hansen; P Dombernowsky; B Hainau
Journal:  Cancer       Date:  1977-06       Impact factor: 6.860

6.  The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer.

Authors:  U Sagman; R Feld; W K Evans; D Warr; F A Shepherd; D Payne; J Pringle; J Yeoh; G DeBoer; A Malkin
Journal:  J Clin Oncol       Date:  1991-06       Impact factor: 44.544

7.  Clinical applications of immunocytochemistry in the monitoring of the bone marrow in small cell lung cancer (SCLC).

Authors:  F G Hay; A Ford; R C Leonard
Journal:  Int J Cancer Suppl       Date:  1988
  7 in total
  2 in total

Review 1.  Mechanisms involved in the metastasis of cancer to bone.

Authors:  F W Orr; P Kostenuik; O H Sanchez-Sweatman; G Singh
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

2.  Immunocytochemical assessment of bone marrow aspirates for monitoring response to chemotherapy in small-cell lung cancer patients.

Authors:  G Pelosi; F Pasini; C Ottensmeier; F Pavanel; E Bresaola; A Bonetti; F Fraggetta; A Terzi; A Iannucci; G L Cetto
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.